A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=7 | Terminated | Sponsor: Sanofi | N=325 ➔ 7 | Active, not recruiting ➔ Terminated; Business decision
Enrollment change • Trial termination • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
|